The pharmacological treatment of opioid addiction-a clinical perspective

被引:84
作者
Lobmaier, Philipp [1 ,2 ]
Gossop, Michael [2 ,3 ]
Waal, Helge [1 ,2 ]
Bramness, Jorgen [2 ,4 ]
机构
[1] Oslo Univ Hosp, Dept Addict Med, Oslo, Norway
[2] Univ Oslo, Norwegian Ctr Addict Res, Oslo, Norway
[3] Kings Coll London, Natl Addict Ctr, London WC2R 2LS, England
[4] Norwegian Inst Publ Hlth, Dept Pharmacoepidemiol, Oslo, Norway
关键词
Opioid addiction; Methadone; Buprenorphine; Naltrexone; Opioid maintenance treatment; Detoxification; Review; BUPRENORPHINE MAINTENANCE TREATMENT; RELEASE ORAL MORPHINE; METHADONE-MAINTENANCE; FOLLOW-UP; HEROIN DEPENDENCE; CONTROLLED-TRIAL; DOUBLE-BLIND; OPIATE DETOXIFICATION; DRUG-USERS; CONVENTIONAL LOFEXIDINE;
D O I
10.1007/s00228-010-0793-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This article reviews the main pharmacotherapies that are currently being used to treat opioid addiction. Treatments include detoxification using tapered methadone, buprenorphine, adrenergic agonists such as clonidine and lofexidine, and forms of rapid detoxification. In opioid maintenance treatment (OMT), methadone is most widely used. OMT with buprenorphine, buprenorphine-naloxone combination, or other opioid agonists is also discussed. The use of the opioid antagonists naloxone (for the treatment of intoxication and overdose) and oral and sustained-release formulations of naltrexone (for relapse prevention) is also considered. Although recent advances in the neurobiology of addictions may lead to the development of new pharmacotherapies for the treatment of addictive disorders, a major challenge lies in delivering existing treatments more effectively. Pharmacotherapy of opioid addiction alone is usually insufficient, and a complete treatment should also include effective psychosocial support or other interventions. Combining pharmacotherapies with psychosocial support strategies that are tailored to meet the patients' needs represents the best way to treat opioid addiction effectively.
引用
收藏
页码:537 / 545
页数:9
相关论文
共 112 条
[1]   Twelve-month maintenance treatment of opium-dependent patients [J].
Ahmadi, J ;
Babaee-Beigi, M ;
Alishahi, M ;
Maany, I ;
Hidari, T .
JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2004, 26 (01) :363-366
[3]   An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research [J].
Amato, L ;
Davoli, M ;
Perucci, CA ;
Ferri, M ;
Faggiano, F ;
Mattick, RP .
JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2005, 28 (04) :321-329
[4]   Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study [J].
Anchersen, Katinka ;
Clausen, Thomas ;
Gossop, Michael ;
Hansteen, Viggo ;
Waal, Helge .
ADDICTION, 2009, 104 (06) :993-999
[5]  
[Anonymous], COCHRANE DATABASE SY
[6]  
[Anonymous], 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002210
[7]  
[Anonymous], COCHRANE DATABASE SY
[8]   French field experience with buprenorphine [J].
Auriacombe, M ;
Fatséas, M ;
Dubernet, J ;
Daulouède, JP ;
Tignol, J .
AMERICAN JOURNAL ON ADDICTIONS, 2004, 13 :S17-S28
[9]   Codeine and clinical impairment in samples in which morphine is not detected [J].
Bachs, L ;
Skurtveit, S ;
Morland, J .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 58 (12) :785-789
[10]   Opioid Maintenance Treatment during Pregnancy: Occurrence and Severity of Neonatal Abstinence Syndrome [J].
Bakstad, Brittelise ;
Sarfi, Monica ;
Welle-Strand, Gabrielle K. ;
Ravndal, Edle .
EUROPEAN ADDICTION RESEARCH, 2009, 15 (03) :128-134